StockNews.com Begins Coverage on TRACON Pharmaceuticals (NASDAQ:TCON)

StockNews.com initiated coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research note issued to investors on Friday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Stock Up 66.7 %

Shares of NASDAQ TCON opened at $0.04 on Friday. The firm has a market cap of $148,316.16, a PE ratio of 0.01 and a beta of 1.43. The company’s fifty day simple moving average is $0.07 and its 200 day simple moving average is $0.48. TRACON Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $14.75.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.